In a phase I trial, a carcinoembryonic antigen glypican-3 (GPC3) peptide vaccine was explored for treating advanced HCC, with 30 of 31 patients (91%) showing a peptide-specific CTL response. The gene discussed is GPC3; the disease is hepatocellular carcinoma.